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Abstract
Activation of different pattern recognition receptors causes distinct profiles of innate immune
responses, which in turn dictate the adaptive immune response. We found that mice had
higher CD4+ T cell expansion to an immunogen, ovalbumin, when coadministered with CpG
than with CL097 in vivo. To account for this differential adjuvanticity, we assessed the activi-
ties of CpG and CL097 on antigen-specific CD4+ T cell expansion in vitro using an OT-II
CD4+ T cell/bone marrow-derived dendritic cell (DC) co-culture system. Unexpectedly, oval-
bumin-stimulated expansion of OT-II CD4+ T cells in vitro was potently suppressed by both
TLR agonists, with CL097 being stronger than CpG. The suppression was synergistically
reversed by co-inhibition of cyclooxygenases 1 and 2, and inducible nitric oxide (NO)
synthase. In addition, stimulation of OT-II CD4+ T cell/DC cultures with CL097 induced
higher levels of CD4+ T cell death than stimulation with CpG, and this CD4+ T cell turnover
was reversed by NO and PGE2 inhibition. Consistently, the co-cultures stimulated with
CL097 produced higher levels of prostaglandin E2 (PGE2) and NO than stimulation with
CpG. CL097 induced higher PGE2 production in DC cultures and higher IFN-γ in the OT-II
CD4+ T cell/DC cultures, accounting for the high levels of PGE2 and NO. This study demon-
strates that the adjuvant activities of immunostimulatory molecules may be determined by
differential induction of negative regulators, including NO and PGE2 suppressing clonal ex-
pansion and promoting cell death of CD4+ T cells.
Introduction
The list of infectious agents prevented by vaccines is growing, assisted by advances in antigen
and adjuvant discovery [1]. Despite this progress, there is an unmet need for effective vaccines
against some of the deadliest infectious diseases including tuberculosis (TB), malaria, and
AIDS. Aluminum salts (Alum) have long been the only adjuvant in vaccines approved for
human use. Alum efficiently elicits antibody responses [2], but is a poor inducer of cell-mediat-
ed immunity [3], which is necessary for protection against intracellular pathogens [4]. New
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adjuvants have been licensed for human use, such as MF59, AS03, and AS04, and many adju-
vant candidates are under development to meet the demand for diverse types of adaptive im-
mune activation [5,6].
Vaccine adjuvants not only enhance the quantitative magnitude of adaptive immune re-
sponses, but also shape their qualitative characteristics [1]. Thus, a protective mode of adaptive
immunity required against a specific pathogen could be improved by rational adjuvant formu-
lation. Adjuvant effects are mediated by the innate immune response [7,8] and dendritic cells
(DCs) are the key immune cells bridging innate and adaptive immunity [9,10]. Engagement of
pattern recognition receptors (PRRs) on DCs by pathogen-associated molecular patterns
(PAMPs) in adjuvant formulations initiates key signaling cascades involving transcription fac-
tors, including nuclear factor (NF)-κB, mitogen-activated protein kinase, interferon regulatory
factor (IRF)-3, and IRF-7 [11,12]. This results in the induction of proinflammatory cytokines
and major histocompatibility complex (MHC) molecules and costimulatory molecule expres-
sion that endow DCs with the ability to prime, expand and polarize naïve T cells [13,14]. Be-
cause individual PRR ligands have been evaluated independently without an experimental
standard or any cross-comparison, the relative adjuvant activities of different PRR agonists
have not been established [15]. This precludes appropriate selection of adjuvants optimized for
specific vaccines.
Toll-like receptors (TLRs) are the most studied PRR in terms of adjuvant development. Par-
ticular TLR ligands activate DCs differently, which may lead to differences in the quality and
quantity of adaptive immune responses [6,13,16]. Synthetic oligodeoxynucleotides (ODN)
containing unmethylated CpG motifs are agonists for TLR9 [17], and are the most studied
class of TLR agonists as adjuvants [15,18]. Imidazoquinolines, ligands for TLR7 and TLR8
[19–21], exert antiviral activity when topically applied on human papilloma virus-induced
warts [22], and adjuvant effects for protein antigens and DNA vaccines [23–25]. TLR7/8 and
TLR9 are both endosomal receptors and the signaling pathways downstream of these receptors
are MyD88-dependent [26].
Defining relative adjuvant effects of different TLR ligands on T cell activation may help op-
timize their selection for different infectious diseases. To that end, we compared the TLR9 ago-
nist CpG1826 and the TLR7 agonist CL097 (a highly soluble derivative of R848 [20]) for their
stimulatory effects on DC and antigen-specific CD4+ T cell activation. We found that CpG was
the more potent adjuvant in terms of enhancing antigen-specific CD4+ T cell expansion. The
lower adjuvanticity of CL097 was attributable to higher induction of the negative regulators of
T cell activation, prostaglandin (PGE2) and nitric oxide (NO) relative to CpG. This study pro-
vides evidence that individual TLR agonists elicit different levels of innate responses resulting
in differential CD4+ T cell responses and that expression of negative regulators is a major deter-
minant of the magnitude of cell-mediated immune responses. In addition, these counter-regu-
latory effects of TLR stimulation suggest the possible use of inhibitors of inflammatory
metabolites in vaccination strategies designed to augment immunogenicity and
protective efficacy.
Materials and Methods
Reagents
The inducible nitric oxide synthase (iNOS) inhibitor NG-methyl-L-arginine acetate salt
(L-NMMA) and the cyclooxygenase (COX)-1/COX-2 inhibitor indomethacin (Indo) were pur-
chased from Sigma (St. Louis, MO). An H-2b-restricted ovalbumin (OVA) class II epitope
(323–339) was purchased from AnaSpec (Fremont, CA). TLR ligands, CpG1826 and CL097,
were purchased from Invivogen (San Diego, CA). All the fluorescent-labeled antibodies were
Nitric Oxide and PGE2 on Adjuvant Activities
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purchased from eBioscience (San Diego, CA). Recombinant mouse IL-2 was purchased from R
& D systems (Minneapolis, MN) and neutralizing anti-IL-2 mAb (clone:JES6-1A12) was from
Biolegend (San Diego, CA).
Mouse immunization
Mice were housed in pathogen-free environment at Animal Medicine facility at the University
of Massachusetts Medical School (UMMS). All animal experiments were carried out in strict
accordance to the guidelines set forth by the National Institutes of Health regarding the use of
laboratory animals under protocols approved by the Institutional Animal Care and Use Com-
mittee (A-1928) at UMMS. Mice were given irradiated food and acidified autoclaved water ad
libitum, and the health and well-being of animals were closely monitored by researchers and
veterinary technicians. Mice were euthanized by CO2 narcosis followed by cervical dislocation.
Wild-type C57BL/6 mice expressing the CD45.2 congenic marker (The Jackson Laboratory,
Bar Harbor, ME) were adoptively transferred intravenously with one million splenocytes ob-
tained from the congenic OT-II transgenic mice. More than 99% of splenocytes isolated from
male OT-II mice express CD45.1 and are transgenic to H-2b-restricted OVA class II epitope
(323–339). 24 h later, mice were immunized subcutaneously with Incomplete Freund’s adju-
vant (IFA) (Sigma) containing 25 μg of OVA protein with or without 20 μg of CpG or CL097.
Equal volumes of IFA and Ag/CpG or Ag/CL097 solution were mixed and 100 μl of the formu-
la was administered to each mouse. Animals were sacrificed after 11 days, and splenocytes
were counted and stained with Alexa 450-labeled anti-CD45.1 and allophycocyanin (APC)
anti-CD4 antibodies. Cells were gated on singlets based on FSC-A/FSC-H, and live cells based
on FSC/SSC and 7-amino-actinomycin D (7-AAD) (Fig 1A). Flow cytometry was performed
on an LSRII flow cytometer (BD Biosciences, San Jose, CA), 500,000 leukocyte-gated events
were collected and data analyzed with FlowJo PC software (TreeStar, Inc.). The number of
OT-II CD4+ T cells from a spleen was calculated based on the number of total splenocytes and
the percentage of CD45.1+/CD4+ cells.
Generation of BMDCs
Bone marrow cells were harvested from C57BL/6 mice. BMDCs were prepared by culturing
bone marrow cells in 10 ml of RPMI1640 medium (Gibco, Gaithersburg, MD) supplemented
with 10 ng/ml granulocyte-macrophage colony-stimulating factor (GM-CSF, R&D Systems),
10% fetal bovine serum (FBS) (BioWhittaker, Walkersville, MD), 100 units/ml of penicillin,
100 mg/ml of streptomycin, and 2 mM glutamine, and 50 μM 2-mercaptoethanol (complete
media) for 8 days. Fresh media was added on days 2 and 5 to maximize DC yield. Non-adher-
ent DCs were collected from 100 mm petri dishes by pipetting, counted and plated.
IL-2 and IFN-γmeasurement
5 x 104 OT-II CD4+ T cells were co-cultured with 1 x 104 DCs in flat-bottom 96-well plates.
The co-cultures were stimulated with OVA protein (25 μg/ml) or OVA peptide (0.1 μM), plus
CpG (1 μg/ml) or CL097 (1 μg/ml) for four days. Supernatants from cultures were collected
and stored in -70°C until use. IL-2 and IFN-γ were measured by a Duoset ELISA kit from R &
D (Minneapolis, MN).
PGE2 measurement
To measure PGE2 produced in DCs stimulated with TLR agonists, DCs were plated in 48-well
plates at 2 x 105 cells per well in 1 ml of complete media in the presence or absence of CpG or
Nitric Oxide and PGE2 on Adjuvant Activities
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CL097 for two days. To measure PGE2 produced in OT-II CD4
+ T cell/DC cultures, purified 5
x 104 OT-II CD4+ T cells and 1 x 104 DCs were plated in flat-bottom 96-well plates in 200 μl of
complete media in the presence or absence of OVA protein (25 μg/ml) with CpG or CL097 for
3 days. Supernatants from cultures were collected and stored in -70°C until use. PGE2 was mea-
sured by a competitive ELISA kit from Enzo (Farmingdale, NY).
Fig 1. Stronger expansion of OT-II CD4+ T cells in mice immunized with OVA plus CpG than with OVA
plus CL097.Mice were adoptively transferred with 1 x 106 splenocytes obtained from OT-II mice and, 24 h
later, immunized with OVA protein (25 μg) with or without CpG (20 μg) or CL097 (20 μg) formulated in IFA.
Mice were sacrificed 11 days post immunization, and the number of expanded OT-II CD4+ T cells were
quantified by cell surface staining of CD4 and CD45.1 followed by flow cytometric analysis. (A) A series of
gating steps depicted in arrows involved gating on total leukocytes (FSC-A/SSC-A), on singlets (FSC-A/
FSC-H), and on live cells (7-AAD/SSC-A). (B) Each FACS plot is an analysis of live splenocytes for one of
eight mice within a group. Cells double positive for CD4 and CD45.1 demarcated in the plot are OT-II CD4+ T
cells. Numbers are the percentages of the OT-II CD4+ T cells in spleens. (C) The total numbers of OT-II CD4+
T cells in spleens were calculated based on the percentages of OT-II CD4+ T cells and known numbers of
splenocytes. Statistical differences were analyzed by one-way ANOVA between treatment groups. Data
shown are representative of three independent experiments. *p<0.002.
doi:10.1371/journal.pone.0123165.g001
Nitric Oxide and PGE2 on Adjuvant Activities
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Nitric oxide measurement
To determine NO levels, nitrite (NO2
-) was measured using the Nitric Oxide Quantitation Kit
purchased from Active Motif (Carlsbad, CA). 4 x 104 OT-II CD4+ T cells and 1 x 104 BMDCs
were plated in 96-well flat-bottom plates and stimulated with OVA protein (25 μg/ml) in the
presence or absence of CpG or CL097 (1 μg/ml) at a total volume of 200 μl for four days. Super-
natants were harvested and diluted by three fold with PBS containing 0.05% Tween-80 before
the assay. Nitrite was measured according to the manufacturer’s protocol. Briefly, 100 μl of di-
luted supernatants were mixed with 50 μl of Griess reagent A and 50 μl of Griess reagent B, and
the color was allowed to develop at room temperature for 10 min. Nitrite standard was serially
diluted ranging from 0.07 to 10 μM. The optical density of the color was measured at 540 mm
with a spectrophotometer.
OT-II T cell proliferation assay
Splenocytes harvested from OT-II transgenic mice were stained with 2 μMCFSE, and then
CD4+ T cells were purified by magnetic separation (Miltenyi Biotec, Auburn, CA). 5 x 105
OT-II CD4+ T cells were co-cultured with 1 x 105 DCs in 48-well plates. The CD4+ T cell/DC
co-cultures were stimulated with OVA protein (25 μg/ml) or OVA peptide (0.1 μM), plus CpG
(1 μg/ml) or CL097 (1 μg/ml) in the presence or absence of L-NMMA (40 μM) or Indo
(10 μM) for 3–5 days as described in figure legends. For 14-day proliferation assays, 5 x 103
OT-II CD4+ T cells were incubated with 1 x 105 BMDCs and stimulated with OVA antigen
and TLR agonists in the presence or absence of the inhibitors for 14 days. At the end of the cul-
ture period, 4 x 105 splenocytes (~60,000 CD4+ T cells) obtained from wild-type C57BL/6 mice
(CD45.2) were added to the cultures immediately before harvest. Cells were stained with Alexa
450 anti-CD45.1 and APC anti-CD4 to calculate the ratio of OT-II CD4+ T cells and wild-type
CD4+ T cells. The formula to calculate OT-II CD4+ T cells is: (%of OT-II CD4+ T cells% of
CD45.1- CD4 T cells) x 60,000. Dead cells were excluded by staining with 7-AAD.
Intracellular staining
To enhance the sensitivity of intracellular cytokine detection, BD GolgiPlug (BD Biosciences)
was added 5 h before the end of culture according to the manufacturer’s recommendation.
Cells were stained with PerCP-Cy5.5 anti-CD4 and then with LIVE/DEAD Aqua Dead cell
stain (Invitrogen, Grand Island, NY) to gate on live CD4+ T cells. Cells were then fixed and per-
meabilized using BD Cytofix/Cytoperm (BD Biosciences) according to the manufacturer’s pro-
tocol. After permeabilized, cells were stained with APC anti-IFN-γ antibody and analyzed by
flow cytometry.
For intracellular staining for FoxP3, cells were first stained with PE anti-CD4, APC anti-
CD25 antibodies, and Aqua Dead cell stain, and fixed and permeabilized with FoxP3 staining
buffer set according to the manufacturer’s instructions (eBioscience). After permeabilization,
cells were stained with Alexa450 anti-FoxP3 antibody.
Measurement of CD4+ T cell death
To measure the cell viability of purified OT-II CD4+ T cells, 5 x 105 OT-II CD4+ T cells stained
with or without CFSE were co-cultured with 1 x 105 DC for 3–4 days. To measure the cell via-
bility of wild-type CD4+ T cells, splenocytes obtained from wild-type CD57BL/6 mice were co-
cultured with 1 x 105 DC for 3 days. At the end of experiment, cells were stained with APC
anti-CD4 antibody and 7-AAD, and analyzed by flow cytometry.
Nitric Oxide and PGE2 on Adjuvant Activities
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In vivo treatment with indomethacin and aminoguanidine hemisulfate
Indomethacin stock solution in DMSO was diluted in PBS for injection. Mice were injected i.p.
with Indo at a dose of 2.5 mg/Kg in 200 μl three times 4 days apart starting from the day of im-
munization [27]. Control mice were injected with PBS containing the same amount of DMSO.
Aminoguanidine hemisulfate (AG) was dissolved in drinking water at 2.5% along with 1% glu-
cose. Mice were given drinking water containing AG for 8 days starting from the day of immu-
nization [28]. Control mice were given drinking water containing 1% glucose.
Statistical analysis
Statistical analysis was performed using Graph Pad Prism v.5.02 (Graphpad Software Inc., La
Jolla, CA) software. Unless otherwise stated, data from independent experiments are shown as
mean ± SD. Comparisons between groups were evaluated with Student’s t-test or One-way
analysis of variance (ANOVA) test followed by Dunnett's Multiple Comparison Test. A p-
value 0.05 was regarded as statistically significant.
Results
CpG promotes greater antigen-specific CD4+ T cell expansion in vivo
than CL097
To investigate if stimulation of different TLRs in vaccination has an impact on the magnitude
of the cellular immune response, we compared the adjuvant candidates CpG and CL097 for
their ability to enhance CD4+ T cell responses. Increasing CD4+ T cell expansion has been pro-
posed as one approach to enhance memory cell generation and vaccine efficacy [29]. For sensi-
tive measurement of CD4+ T cell expansion in vivo, we adoptively transferred splenocytes
containing OVA-specific T cell receptor transgenic CD4+ T cells obtained from OT-II mice
into wild-type C57BL/6 recipients and monitored their expansion after immunization. OT-II
CD4+ T cells carry the congenic marker CD45.1 that is used to distinguish OT-II CD4+ T cells
from CD4+ T cells of the recipient wild-type mice, which express CD45.2. One day after OT-II
CD4+ T cell transfer, recipient mice were immunized subcutaneously with OVA protein in the
presence or absence of CpG or CL097 formulated in IFA. The water-in-oil emulsion IFA was
chosen as a delivery vehicle for the unbiased packaging of CpG and CL097. 11 days after im-
munization, harvested splenocytes were stained for CD4 and CD45.1 followed by flow cyto-
metric analysis to enumerate the OT-II CD4+ T cells. OT-II CD4+ T cells significantly
expanded by immunization with OVA alone compared to the control of IFA without antigen,
but the addition of CpG to OVA further increased CD4+ T cell expansion over OVA alone (Fig
1B and 1C). In contrast, adding CL097 to the formula containing OVA did not significantly in-
crease CD4+ T cell expansion over OVA alone (Fig 1B and 1C). This poor adjuvant activity of
CL097 was not due to the weak in vivo activities of CL097 in the preparation because the
CL097 formula enhanced OT-II CD4+ T cells comparable to the CpG formula up until four
days post immunization (S1 Fig). This observation suggests that there are differences among
TLR agonists in their activity as adjuvants to stimulate CD4+ T cell expansion.
OT-II CD4+ T cell proliferation is suppressed by TLR agonists
independent of IL-2
To further investigate the direct effects of the TLR agonists on the DC function to prime CD4+
T cells, we developed an in vitro priming assay using OT-II T cells. Congenic DCs from wild-
type C57BL/6 mice and OT-II CD4+ T cells were stimulated with CpG or CL097 in the pres-
ence of OVA protein or peptide and then CD4+ T cell expansion was assessed by CFSE
Nitric Oxide and PGE2 on Adjuvant Activities
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dilution. It has been shown that DCs differentiated from bone marrow progenitor cells with
GM-CSF are efficient antigen-presenting cells because they constitutively express high levels of
costimulatory molecules [9]. Consistent with that report, we found that DCs loaded with OVA
peptide and, to a lesser extent, OVA protein induced CD4+ T cell proliferation in the absence
of TLR stimulation (Fig 2A). Addition of CpG or CL097 suppressed CD4+ T cell proliferation
induced by both OVA peptide and protein alone (Fig 2A), which was unexpected given their in
vivo effects. This suppression in the in vitro priming assay was more strongly mediated by
CL097 than CpG when OVA peptide was used (Fig 2A) and directly correlated with reduced
production of the T cell growth factor IL-2 (Fig 2B). Although T cell expansion in response to
OVA protein was completely blocked both by CpG and CL097 (Fig 2A), IL-2 production was
lower in cultures stimulated with CL097 (Fig 2C). Reconstitution with exogenous IL-2 failed to
restore CD4+ T cell proliferation in DC co-cultures with OVA and CL097 present, indicating
that the suppressive effect of CL097 did not result from relative IL-2 deficiency (Fig 3A). Addi-
tion of exogenous IL-2 decreased CD4+ T cell expansion in cultures stimulated with OVA only,
suggesting a regulatory role for IL-2 in this culture system. Consistent with that model, neutral-
izing anti-IL-2 mAb potently enhanced the CD4+ T cell proliferation induced by OVA alone
(Fig 3B). Blocking IL-2 failed to enhance CD4+ T cell expansion suppressed by CL097, suggest-
ing that IL-2 is not involved in the suppression by CL097. The absence of IL-2 responsiveness
is not due to reduction of the IL-2 receptor CD25 because the addition of CpG and CL097 fur-
ther increased the CD25 levels induced by OVA stimulation (Fig 3C). Stimulation with CpG
and CL097 increased not only effector cells but also FoxP3+ regulatory T cells.
Suppression of OT-II T cell proliferation by TLR agonists is mediated by
prostaglandins and NO
Since PGE2 and NO are known to suppress T cell proliferation in vitro [30–39], we speculated
that they might play a role in the suppression of CD4+ T cell expansion induced by CpG and
CL097. We measured secreted PGE2 levels from DC cultures and from OT-II CD4
+ T cell/DC
co-cultures. PGE2 levels were significantly higher in DCs stimulated with CL097 than with
CpG (Fig 4A). PGE2 levels were also found to be higher in OT-II CD4
+ T cell/DC co-cultures
stimulated with CL097 in the presence of OVA protein (Fig 4B). Consistent with the result
from DC cultures, PGE2 levels were higher in the co-cultures stimulated with CL097 in the ab-
sence of OVA protein (Fig 4B). This indicates that the tendency of CL097 to induce high PGE2
production occurs at both innate and adaptive levels. To determine NO levels, co-cultures of
OT-II CD4+ T cells and DCs were stimulated with OVA protein or OVA peptide in the pres-
ence or absence of CpG or CL097 for four days, and culture supernatants were harvested to
measure NO2
- accumulation. CL097-stimulated cultures had a higher concentration of NO2
-
than CpG-stimulated and OVA alone cultures (Fig 4B). Consistent with the fact that IFN-γ is
the major inducer of NO [40] and PGE2 [41], IFN-γ levels were highest in cultures stimulated
with CL097 (Fig 4C). This implied that higher levels of IFN-γ/NO/ PGE2 may have been re-
sponsible for higher suppression of CD4+ T cell proliferation by CL097 in vitro and possibly
for higher CD4+ T cell expansion in mice immunized with CpG stimulation than CL097 stimu-
lation. To confirm that PGE2 and NO were responsible for the suppression of CD4
+ T cell ex-
pansion in vitro, we tested the effects of the COX-1/COX-2 inhibitor Indo and the iNOS
inhibitor L-NMMA. Co-cultures of DCs and OT-II CD4+ T cells were pulsed with OVA pro-
tein alone or OVA protein plus CpG or CL097 in the presence or absence of Indo or
L-NMMA. The iNOS inhibitor minimally enhanced CD4+ T cell expansion in CpG and
CL097-treated cultures, and treatment with Indo alone produced a modest increase in T cell
expansion induced by OVA-pulsed DCs stimulated with CpG or CL097 (Fig 5A). Of note, the
Nitric Oxide and PGE2 on Adjuvant Activities
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Fig 2. Stimulation of DCs with CpG and CL097 suppresses OT-II CD4+ T cell proliferation and IL-2
production.OT-II CD4+ T cell/DC co-cultures stimulated with TLR ligands and OVA peptides were harvested
to assess CD4+ T cell proliferation (A) and IL-2 production (B and C). (A) OT-II CD4+ T cells stained with
CFSE were co-cultured with DCs and stimulated with OVA peptide (0.1 μM) or OVA protein (25 μg/ml) in the
presence or absence of CpG or CL097 (1 μg/ml) for four days until analyzed by flow cytometry. The range
and number in each histogram represent cells that proliferated at least one time. Supernatants from cultures
stimulated with OVA peptide (B) or OVA protein (C) in the presence or absence of CpG (1 μg/ml) or CL097
(1 μg/ml) for four days were harvested to measure IL-2 levels by ELISA. Statistical differences between
treatments in OVA stimulated cells were analyzed by one-way ANOVA. Data are expressed as mean ± SD of
triplicate wells. Data shown are representative of three independent experiments. *p<0.05; **p<0.005.
doi:10.1371/journal.pone.0123165.g002
Nitric Oxide and PGE2 on Adjuvant Activities
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Fig 3. Suppression of OT-II CD4+ T cell expansion by TLR agonists is IL-2 independent.OT-II CD4+ T
cells/DC co-cultures were stimulated with OVA protein (25 μg/ml) in the presence or absence CL097 (1 μg/
ml) for 5 days. (A) Various concentrations of recombinant IL-2 or (B) neutralizing anti-IL-2 antibody were
added to the cultures during stimulation. The two sets of ranges and numbers in each histogram represent
cells that proliferated more than three times (upper) and at least one time (lower). (C) The cultures were
stimulated with OVA protein in the presence or absence of CpG or CL097 for three days, and the cells were
stained for CD25 and FoxP3 to measure expression levels of CD25 on FoxP3- and FoxP3+ CD4+ T cells.
Data shown are representative of three independent experiments.
doi:10.1371/journal.pone.0123165.g003
Nitric Oxide and PGE2 on Adjuvant Activities
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Fig 4. CL097 induces higher levels of PGE2, NO2
- and IFN-γ than CpG. (A) DCs were stimulated with CpG
or CL097 at concentrations of 0.2, 1, and 5 μg/ml for 2 days, and PGE2 levels were measured from culture
supernatants. Data shown are representative of two independent experiments. (B) OT-II CD4+ T cell/DC co-
cultures were stimulated with OVA protein (25 μg/ml) in the presence or absence of 1 μg/ml CpG or CL097 for
3 days, and PGE2 levels were measured. Data shown are representative of two independent experiments.
(C) OT-II CD4+ T cells/DC co-cultures were stimulated in the presence or absence of TLR agonists and OVA
Nitric Oxide and PGE2 on Adjuvant Activities
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combination of L-NMMA and Indo synergistically enhanced antigen-stimulated T cell prolif-
eration in the presence of TLR ligands (Fig 5A), indicating that CpG and CL097 suppress T cell
expansion through production of both NO and PGE2. Treatment either with L-NMMA or
Indo substantially enhanced CD4+ T cell expansion in cultures stimulated with OVA alone, in-
dicating that the moderate amounts of NO and PGE2 induced by OVA (Fig 4) are functionally
significant. In addition to the proliferative response, Indo and L-NMMA synergistically en-
hanced IFN-γ production induced by OVA plus CpG or OVA plus CL097 as demonstrated by
intracellular cytokine staining (Fig 5B). On the other hand, IFN-γ production induced by OVA
alone was not enhanced by either inhibitor. These results suggest that PGE2 and NO stimulated
by TLR stimulation not only inhibit CD4+ T cell expansion, but suppress IFN-γ production by
CD4+ T cells.
CL097 is a potent inducer of CD4+ T cell death
Because both NO and PGE2 have been implicated in cell death pathways [42,43], we investigat-
ed if these modulators induced by TLR agonists have any effects on CD4+ T cell viability.
OT-II CD4+ T cell/DC co-cultures were stimulated with CpG or CL097 in the presence or ab-
sence of OVA protein for three days, and the viability of CD4+ T cells were measured by
7-AAD staining. Interestingly, stimulation with CL097 without OVA potently increased,
whereas CpG decreased 7-AAD-positive dead OT-II CD4+ T cells, compared to no agonist
control (Fig 6A). To investigate if this CL097-induced cytotoxicity also occurs in non-transgen-
ic wild-type CD4+ T cells, splenocytes of wild-type mice were cocultured with DC and stimu-
lated with CpG or CL097 without OVA. Under this culture condition, stimulation with CL097
also reduced CD4+ T cell viability, relative to CpG and no agonist control (Fig 6B). In addition,
CL097-induced CD4+ cell death was rescued equally by L-NMMA and Indo. The source of
PGE2 in the absence of antigenic stimulation can be DC production of PGE2 (Fig 4A and 4B)
and we also found that CD4+ T cell/DC cocultures stimulated with CL097 in the absence of
OVA produced higher levels of IFN-γ than stimulation with CpG (S2 Fig), which is thought to
elicit NO as well as PGE2. In the presence of OVA, addition of CL097 induced higher CD4
+ T
cell deaths than addition of CpG, which slightly increased the 7-AAD-positive cells (Fig 6A).
Under culture conditions with OVA, both L-NMMA and Indo reduced OT-II CD4+ T cell
death caused by CL097 with L-NMMA being more potent. These results suggest that CD4+ T
cell death by PGE2 and NOmay constitute mechanisms for the different adjuvanticity of CpG
and CL097 (Fig 1).
CL097 drives T cell expansion in the presence of L-NMMA and Indo in
2-week cultures
The CFSE dilution assay uses 5 x 105 OT-II CD4+ T cells, which might not reflect the condi-
tions of T cell activation in vivo where the frequency of antigen-specific T cell precursors is
low. To model a more physiologic condition, we set up co-cultures with 5 x 103 OT-II T cells.
The OT-II/DC co-cultures were stimulated for 2 weeks with OVA in the presence or absence
of the TLR agonists and iNOS/COX inhibitors. Following the incubation period, 4 x 105
protein (25 μg/ml) for four days, and supernatants were collected to measure NO2
- by Griess assay. Data
shown are representative of three independent experiments. (D) OT-II CD4+ T cells/DC co-cultures were
stimulated in the same conditions mentioned above for 4 days, and supernatants were collected to measure
IFN-γ by ELISA. Data shown are representative of three independent experiments. Statistical differences
between treatments were analyzed with one-way ANOVA. The graph shows the mean ± SD of triplicate
wells. *p<0.05; **p<0.005.
doi:10.1371/journal.pone.0123165.g004
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Fig 5. Inhibition of COX-1/COX-2 and iNOS synergistically enhances OT-II CD4+ T cell proliferation
and IFN-γ production in vitro. (A) CFSE-stained OT-II CD4+ T cells were mixed with congenic DCs and
stimulated with OVA protein with or without TLR agonists in combination with L-NMMA (40 μM) or Indo
(10 μM) for 4 days. Proliferation of OT-II CD4+ T cells were analyzed by CFSE dilution. The range and
number in each plot indicate cells that proliferated at least one time. Data shown are representative of two
independent experiments. (B) OT-II CD4+ T cells were mixed with congenic DCs and stimulated with OVA
Nitric Oxide and PGE2 on Adjuvant Activities
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splenocytes from C57BL/6 mice (CD45.2+) were added to the culture to allow for the enumera-
tion of CD45.1 OTII CD4+ T cells by the ratio of CD45.1+ to CD45.2+ CD4+ T cells. Results
protein with or without TLR agonists and inhibitors for 4 days. GolgiPlug was added to the cultures to inhibit
exocytosis of intracellular IFN-γ at 5 h before harvest. Cells were first stained for CD4, fixed, and stained for
intracellular IFN-γ. The numbers in the upper right quadrant signifies the percentage of IFN-γ positive cells
among CD4+ T cells. Dead cells were excluded using a fixable live/dead dye. Data shown are representative
of two independent experiments. iNOS: inducible nitric oxide synthase; COX: cyclooxygenase.
doi:10.1371/journal.pone.0123165.g005
Fig 6. TLR7 stimulation causes elevation of CD4+ T cell deathmediated by NO and PGE2. (A) Co-cultures of 5 x 10
5 OT-II CD4+ T cells and 1 x 105 DC
were stimulated with 1 μg/ml CpG or 1 μg/ml CL097 in the presence or absence of 25 μg/ml OVA protein for three days. CL097, but not CpG, increased OT-II
CD4+ T cell death regardless of antigenic stimulation. (B) 1 x 106 splenocytes from wild-type mice were mixed with 1 x 105 DC and then stimulated with
CL097 in the presence or absence of L-NMMA or Indo for three days. CD4+ T cell death was reduced by L-NMMA and Indo. (C) Co-cultures of 5 x 105 OT-II
CD4+ T cells stained with CFSE and 1 x 105 DC were stimulated with OVA protein plus CL097 in the presence or absence of L-NMMA or Indo for four days.
Data are representative of two independent experiments.
doi:10.1371/journal.pone.0123165.g006
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from the 2 week T cell proliferation system did not exactly reproduce the short-term T cell pro-
liferation results measured by CFSE dilution. As shown in Fig 7, the proliferation of OT-II T
cells was low in the absence of the inhibitors regardless of OVA and TLR ligand stimulation.
During the 2-week incubation, Indo dominantly improved the expansion of OT-II T cells in all
stimulations. Dual inhibition of NO and PGE2 synergistically enhanced CD4
+ T cell expansion
only when stimulated with OVA plus CL097, but not with OVA alone or with OVA plus CpG.
This suggests that CL097 may exert adjuvant activity stronger than CpG to enhance CD4+ T
cell expansion when both prostaglandins (PGs) and NO are inhibited.
Neither PGE2 nor NO inhibition enhances the expansion of CD4
+ T cells
in vivo
Our in vitro observations indicate that higher induction of PGE2 and NO by CL097 than CpG
may account for the low adjuvanticity of CL097 compared to CpG (Fig 1). To investigate the in
vivo relevance of our in vitro data, we treated mice with AG and Indo to inhibit NO and PGE2
production, respectively. AG was given in drinking water [28] and Indo was injected i.p. three
times at four day intervals [27]. Unlike the in vitro observation that inhibiting both NO and
PGE2 synthesis enhanced CD4
+ T cell expansion, neither Indo nor AG treatment enhanced
CD4+ T cell expansion after immunization with OVA plus CpG (Fig 8A) or CL097 (Fig 8B).
Fig 7. Simultaneous inhibition of COX-1/COX-2 and iNOS synergistically enhances OT-II CD4+ T cell
proliferation stimulated with OVA protein plus CL097 in 2-week culture. 5 x 103 OT-II CD4+ T cells were
mixed with 1 x 105 congenic DCs, and incubated with a combination of OVA protein, CpG, CL097, L-NMMA
(40 μM), and Indo (10 μM) for 2 weeks to measure long-term CD4+ T cell expansion in vitro. At the end of the
culture period, 4 x 105 splenocytes fromWT C57BL/6 mice (CD45.2) were spiked into the cultures to
calculate the number of OT-II CD4+ T cells (CD45.1). Cells were stained with anti-CD45.1 and anti-CD4
antibody to measure the expansion of OT-II CD4+ T cells. 7-AAD was used to exclude dead cells in the
analysis. Shown are mean numbers of OT-II CD4+ T cells of triplicate wells ± SD. Statistical differences were
analyzed by one-way ANOVA. Data are expressed as mean ± SD of triplicate wells. Data shown are
representative of three independent experiments. **p<0.001. iNOS: inducible nitric oxide synthase;
COX: cyclooxygenase.
doi:10.1371/journal.pone.0123165.g007
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This negative result with systemic inhibition may reflect the complexity of NO and PGE2 sig-
naling pathways operating in a more complex in vivo environment.
Discussion
Natural and synthetic adjuvants are being actively discovered and developed to support a grow-
ing trend preferring better defined subunit vaccines over live/whole vaccines [15]. However,
there is currently no strong evidence to inform the rational selection of specific PRR agonists as
adjuvants for a particular vaccine. We found that CpG, as an adjuvant, promoted stronger
CD4+ T cell expansion than CL097 in mice. This difference in adjuvant potential of CpG and
CL097 was delineated in the in vitro studies demonstrating that CpG was a weaker inducer of
NO and PGE2 than CL097. This study provides evidence that adjuvant activity of PRR agonists
is influenced by concurrent induction of regulatory factors. When comparing different PRR ag-
onists, differential expression of regulatory products, such as NO and PGE2, should be consid-
ered and might be utilized as biomarkers of adjuvanticity.
One strategy to enhance vaccine efficacy is to increase the size of memory T cell popula-
tions. Because the size of memory T cell pools is proportional to the level of initial clonal ex-
pansion after antigenic stimulation [44], increasing the magnitude of the T cell expansion has
been suggested to enhance memory generation [29]. Thus, we measured the expansion of anti-
gen-specific CD4+ T cells to evaluate the adjuvanticity. We found that the adjuvant activity of
the TLR9 ligand CpG was 10 times more potent than the TLR7 ligand CL097 in mice immu-
nized with OVA. This result demonstrates that there exists a hierarchy among TLR agonists in
promoting CD4+ T cell expansion that warrants further studies to define relative adjuvant ac-
tivities of TLR agonists, which would enable informed decisions on which TLR agonists are se-
lected for an adjuvant formulation.
To identify determinants accounting for the difference in adjuvanticity between CpG and
CL097, we set up an in vitro co-culture of OT-II CD4+ T cells and DCs to model CD4+ T cell
priming in vivo. TLR stimulation is required for DCmaturation that drives antigen-specific T
cell expansion in vivo [45]. Despite this requirement, BMDCs in our in vitro T cell priming assay
Fig 8. Expansion of OT-II CD4+ T cells are not enhanced by systemic treatment with Indo or AG.Mice
were adoptively transferred with 1 x 106 splenocytes obtained from OT-II mice and, 24 h later, immunized with
25 μg OVA protein with or without 20 μg CpG (A) or the same dose of CL097 (B) formulated in IFA. To inhibit
NO, mice were given drinking water containing 2.5% AG and 1% glucose. To inhibit PGE2, mice were
injected i.p. with Indo at a dose of 2.5 mg/Kg on the day of immunization and two more injections after 4 and 8
days. Mice were sacrificed 11 days post immunization, and the number of expanded OT-II CD4+ T cells were
quantified by cell surface staining of CD4 and CD45.1 followed by flow cytometric analysis. The total numbers
of OT-II CD4+ T cells in spleens were calculated based on the percentages of OT-II CD4+ T cells and known
numbers of splenocytes. Statistical differences were analyzed by one-way ANOVA between treatment
groups. *p<0.05. AG: aminoguanidine hemisulfate; Indo: indomethacin.
doi:10.1371/journal.pone.0123165.g008
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were capable of driving antigen-specific T cell expansion without TLR stimulation, and the addi-
tion of CpG and CL097 paradoxically inhibited OVA-specific T cell proliferation as determined
by CFSE dilution. This discrepancy can be explained in the nature of the DC and TCR-transgenic
CD4+ T cells used for these co-cultures. DCs differentiated from bone marrow progenitors in
media containing GM-CSF are highly efficient antigen-presenting cells with high basal expres-
sion of MHC II and costimulatory molecules [46]. BMDCs produced in this manner are capable
of driving the expansion of even Treg cells, which are known to be anergic otherwise [47]. Never-
theless, the current in vitro system provided novel insight into the roles of suppressive signals on
adjuvant activities.
We found that CL097 more strongly suppressed OVA-specific T cell expansion than CpG
in the in vitro culture system, which could account for the lower adjuvanticity of CL097 that
we observed in vivo. Factors that determine the differential suppression of T cell expansion by
CpG and CL097 might predict adjuvanticity. Interestingly, this differential suppression of
CD4+ T cell expansion directly correlated with IL-2 concentration in the cultures. Because IL-2
is a critical growth factor for T cell proliferation [48], we considered whether suppression of
IL-2 was responsible for the suppression of the CD4+ T cell expansion in our culture system.
Reconstitution and blocking experiments showed that this was not the case and, conversely,
that IL-2 acted as a negative regulator of CD4+ T cell expansion in the cultures. It has been
shown that IL-2 has both immunostimulatory and immunosuppressive roles depending on the
context [49]. The immunosuppressive effect conferred by IL-2 is to potentiate Fas-induced ac-
tivation-induced cell death [50,51]. This is a possible explanation for our in vitro results since
we observed that adding exogenous IL-2 reduced the viability of CD4+ T cells, while neutraliz-
ing endogenous IL-2 enhanced viability as determined by 7-AAD staining. On the other hand,
reconstitution or blocking of IL-2 did not restore CD4+ T cell expansion suppressed by CL097
stimulation, indicating that other regulators are involved. It is still to be determined whether
IL-2 suppression by TLR agonists is an important issue in terms of their potential as
vaccine adjuvants.
To identify immune components responsible for the suppression of CD4+ T cell expansion
induced by the TLR agonists, we considered NO and PGE2 because they are recognized as neg-
ative regulators of T cell expansion [30–39]. As determined by CFSE dilution, the cell cycle ar-
rest imposed by CpG and CL097 was partially lessened by either L-NMMA or Indo and the
combination of the two inhibitors synergistically restored CD4+ T cell proliferation. This syn-
ergism of iNOS/COX double inhibition indicates that NO and PGE2 non-redundantly suppress
T cell proliferation, which is consistent with the proposed mechanisms for these regulatory ac-
tivities. Bingisser et al. [35] reported that suppression of T cell proliferation by NO is due to de-
phosphorylation of Janus kinase 3, and the signal transducer and activator of transcription 5,
activation of guanylate cyclase, and resulting cyclic GMP production. On the other hand, PGE2
was shown to inhibit T cell activation by increasing cyclic AMP which inhibits cytosolic in-
creases in [Ca2+] [52] and diacylglycerol and inositol phosphate production [53,54]. The obser-
vation that CL097 more potently induced NO and PGE2 than CpG is intriguing and might
account for the poor in vivo adjuvanticity of CL097 compared to CpG.
The synergistic enhancement of IFN-γ production by inhibition of NO and PGE2 reflects
the complex regulatory roles of the metabolites. It has been shown that IFN-γ stimulation in-
duces both NO and PGE2 [40,41], and conversely, NO and PGE2 suppress IFN-γ production
[55,56]. Based on these observations, a series of events involving IFN-γ and NO/PGE2 in in-
flammation can be postulated. As NO and PGE2 accumulate in inflamed tissues, IFN-γ levels
likely decline due to the negative feedback loop. Reduced IFN-γ levels would in turn reduce
NO production. Unlike NO, there exists a positive feedback mechanism between PGE2 [41]
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and COX-2, which may sustain PGE2 levels. Further studies are needed to define the dynamics
of PGE2, NO, and IFN-γ levels in the context of vaccination and chronic infections.
Potent induction of CD4+ T cell death by CL097 has important implications in the use of
TLR7 agonists as a vaccine adjuvant. This observation is not limited to murine cells because
stimulation of human PBMCs with imiquimod induced higher CD4+ T cell turnover than
other TLR agonists including LPS [57]. In the study, authors found that TLR7 stimulation pref-
erentially killed CD4+ T cells over CD8+ T cells. We elucidate in this report that CL097-in-
duced CD4+ T cell death was mediated by both NO and PGE2. These results warrant further
investigation into whether CD4+ T cell death by TLR7 agonists through NO and PGE2 have
implications in vaccine efficacy. Of particular interest, TLR7 stimulation induced CD4+ T cell
death, whereas TLR9 stimulation is protective in the absence of antigen stimulation, This indi-
cates that the adjuvanticity of a TLR agonist may be determined prior to antigen stimulation
through modulation of CD4+ T cell turnover.
In the CD4+ T cell proliferation assay measured by CFSE dilution, we used 5 x 105 OT-II
CD4+ T cells per well and cultured them for 3–4 days. High numbers of monoclonal, transgenic
CD4+ T cells in in vitro cultures may create too much competition for antigen stimulation and
the cultures cannot be maintained> 6 days due to overpopulation. To generate a culture con-
dition closer to the in vivomilieu, we set up a long-term OT-II T cell stimulation assay with a
low starting number of cells (5 x 103 cells per well) that ran for 2 weeks. Results from the long-
term cultures were different from (and not predicted by) the data generated using higher initial
numbers of CD4+ T cells in short-term culture. First, OT-II CD4+ T cells in long-term cultures
that were stimulated with OVA stopped proliferating early regardless of the presence of the
TLR agonists. This early termination of expansion was not due to depletion of nutrients or an-
tigen, because media was replaced during the culture period and OT-II CD4+ T cells continu-
ously proliferated in the presence of Indo. Unlike the short-term CFSE dilution experiments
where L-NMMA alone increased proliferation of OT-II cells in the presence of OVA, iNOS in-
hibition had no impact on CD4+ T cell expansion in long-term cultures stimulated with OVA
alone or OVA plus CpG or CL097. Furthermore, the synergistic elevation of CD4+ T cell ex-
pansion by L-NMMA plus Indo that was observed in the short-term culture system with OVA
in combination with CpG or CL097 was only observed in the long-term cultures stimulated
with OVA and CL097 together. The basis for these differences between the two culture condi-
tions is presently unknown but may reside in the interaction of NO and PGE2 synthetic path-
ways, higher stability of PGE2 than NO, and positive feedback loop between PGE2 and COX-2
[41,58,59]. Whatever mechanisms are involved, these experiments revealed the potential for si-
multaneous inhibition of iNOS and COXs to enhance the adjuvant activity of TLR agonists.
Under in vivo conditions, there are multiple cell types contributing and responding to NO
and PGE2 that may impact on adaptive immune responses after vaccination. There is constitu-
tive, low level production of NO by neuronal, endothelial nitric oxide synthase, and prosta-
noids by COX-1 to conduct essential physiologic functions and homeostasis. Under
inflammatory conditions, iNOS and COX-2 are induced in immune cells and generate a large
amount of NO and PGs [60,61]. After vaccination, the first wave of NO/PGE2 production
comes from leukocytes including neutrophils, monocytes, macrophages, and DCs, recruited to
the injection sites. These cells transport antigens into draining lymph nodes for the initiation
of the adaptive immune response [62]. Thus, a second wave of NO/PGE2 production takes
place in the draining lymph nodes mediated by recruited and lymph node resident leukocytes.
If a vaccine material is designed to be directly delivered to lymph nodes through lymph ducts,
resident cells in lymph node would be the major source of the metabolites.
Despite the strong in vitro evidence, neither Indo nor AG treatment enhanced CD4+ T cell
expansion in mice immunized with OVA plus CpG or OVA plus CL097. The failure to
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improve CD4+ T cell proliferation may be explained by diverse, often opposing effects that NO
and PGE2 each exert in the immune system [61,63,64]. For example, PGE2 enhances influx of
macrophages, neutrophils, and DC to injection sites, and DC activation and migration to
draining lymph nodes, while it inhibits DC antigen presentation and T cell priming, and pro-
motes regulatory CD4+ T cells and myeloid derived suppressor cells [60,63,64]. Likewise, NO
has been shown to have pro-inflammatory/anti-inflammatory, pro-proliferative/anti-prolifer-
ative, and pro-apoptotic/anti-apoptotic properties in immune cells [43,65–69]. Thus, non-tar-
geted, systemic inhibition of NO/PGE2 production may not be an optimal way to determine
the role of mediators in adjuvant activities because the benefits of NO/PGE2 inhibition may be
offset by the loss of the immunostimulatory effects of NO/PGE2.
The poor performance of CL097 as an adjuvant, as compared to CpG in our study is in con-
trast to the current interests in promoting TLR7 agonists as vaccine adjuvants. For humans,
TLR7/8 agonists have an advantage over TLR9 agonists because TLR7/8 are expressed on mul-
tiple DC subsets, whereas TLR9 is expressed only in plasmacytoid DCs [70]. The adjuvant ac-
tivity of CpG ODN has been well established in preclinical studies [15], and CpG is being
tested in clinical studies as a component of IC31 and AS15 [71]. On the other hand, there is
not enough evidence to determine the utility of TLR7/8 as a target for a vaccine adjuvant [15]
despite that the TLR7 agonist imiquimod has been licensed as a topical formulation to treat
genital warts, actinic keratosis, basal cell carcinoma, and lentigo maligna [72]. Considering the
weak adjuvanticity of CL097 in our hands, it is conceivable that TLR7/8 agonists may be more
suitable for therapeutic than prophylactic use. However, the utility of TLR7/8 agonists as an ad-
juvant should be evaluated using more optimized TLR7/8 agonists in diverse vaccine formulas
and injection routes.
In summary, we show that the ultimate adjuvant potential of CpG and CL097 may be deter-
mined by their differential induction of immunoregulatory factors like NO and PGE2. The syn-
ergistic enhancement of T cell expansion by dual inhibition of iNOS and COX-1/COX-2 in
vitromay also reflect endogenous mechanisms that blunt T cell immunity to infectious diseases
with chronic inflammation, such as TB [73], and might provide potential targets for host-di-
rected therapies. In the context of vaccination, the generation of NO and PGE2 may limit the
efficacy of vaccines designed to boost cell-mediated immunity. Inhibiting these mediators in a
way that enhances vaccine-induced immune priming might enhance protective efficacy against
diseases like TB where traditional vaccination strategies have so far been disappointing.
Supporting Information
S1 Fig. CpG and CL097 equally enhance OT-II CD4+ T cell expansion to OVA stimulation
up to four days post immunization. Splenocytes from OT-II mice stained with CFSE were
adoptively transferred to WT mice at 1 x 106 per mouse. The WT mice were then immunized s.
c. with OVA formulated in IFA in the presence or absence of CpG or CL097. Four days later,
inguinal lymph nodes were collected to examine the proliferative responses of OT-II CD4+ T
cells. The two sets of ranges and numbers in each histogram represent cells that proliferated
more than seven times (upper) and at least one time (lower).
(TIFF)
S2 Fig. CL097 induces higher IFN-γ than CpG in the absence of antigenic stimulation. Pu-
rified CD4+ T cells of OT-II mice were co-cultured with DCs in the presence of CpG or CL097
for four days. IFN-γ levels were measured from culture supernatants by ELISA. The graph
shows the mean ± SD of triplicate wells. Data are representative of four independent experi-
mentsp<0.005.
(TIFF)
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